Bexsero
GSK launches patent infringement action against Pfizer
November 7, 2016Sales and Marketing Bexsero, trumenba
GlaxoSmithKline has filed a patent infringement lawsuit against rival Pfizer over the alleged copying of its popular meningococcal group B …
GSK and UK government agree meningitis B vaccine deal
March 30, 2015Sales and Marketing AstraZeneca, Bexsero, GSK, Novartis, meningitis v, vaccines
The UK government has agreed a deal with GlaxoSmithKline to provide its meningitis B vaccine Bexsero on the NHS, after …
Novartis earns EMA and FDA nods for Jakavi and Bexsero
January 26, 2015Sales and Marketing Bexsero, Cancer, EU, FDA, Jakavi, Novartis, US, meningitis, ruxolitinib
Novartis has secured the regulatory go-ahead for two of its drugs, after the EMA recommended Jakavi for a rare blood …
Bexsero and Sirturo clear winners at UK Prix Galien Awards
October 2, 2014Medical Communications, Research and Development, Sales and Marketing 2014, Bexsero, Janssen, Novartis, awards, prix galien, sirturo
The first TB medication to be approved in four decades and the first ever vaccine to treat invasive meningococcal disease …
Novartis must drop vaccine price, says UK govt
August 5, 2014Medical Communications, Sales and Marketing Bexsero, Novartis, innoculation, meningococcal vaccine
Novartis will have to significantly lower the price of its meningococcal B vaccine if it wants a lucrative UK inoculation …
UK rejects meningitis B vaccine Bexsero
July 25, 2013Sales and Marketing Bexsero, Novartis, Vaccine, meningitis b
The UK government’s department for vaccinations has stunned observers by failing to back the world’s only vaccine for meningitis B. …
Novartis’ 2012 results flat
January 24, 2013Sales and Marketing Bexsero, Jakavi, Novartis, generics, results
Generic competition has put a dent in Novartis’ financial results for 2012, with net sales down 3% year on year …
EU approval for meningitis vaccine
January 23, 2013Sales and Marketing Bexsero, CHMP, Novartis, meningitis
European regulators have approved Novartis’ Bexsero, making it the first broad coverage vaccine to target the leading cause of meningitis. …
Novartis submits meningococcal vaccine Bexsero for European approval
December 23, 2010Sales and Marketing Bexsero, MenB, Novartis, Vaccine, bacterial meningitis, bloodstream infection sepsis, meningococcal disease, meningococcal vaccine
Novartis has submitted its meningococcal vaccine Bexsero to European regulators for marketing approval. If approved the drug will be the …
Latest content
